Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
November 9, 2021 6:50 AM ESTQ3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share Expect to receive approval for Abbreviated New Drug Application (ANDA) for vasopressin; December 15, 2021 GDUFA date Received favorable district court decision that Eagles proposed vasopressin product does not infringe any of the patents Par asserted against Eagle Entered into worldwide licensing agreement for CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe bacterial pneumonia Licensed U.S. commercial rights to landiolol, a beta-1... More
